No matches
Dermatology

The Chronic Nature of CSU: Understanding Disease Duration and Persistence

Dr. Elena Netchiporouk discusses the chronic nature of CSU at EADV 2025.
Elena Netchiporouk
MD, MSc, FRCPC
Elena Netchiporouk

Related resources

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

expert video
Disease Modification Concepts in AD

Disease Modification Concepts in AD

expert video
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

expert video
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

videoanimation
How type 2 cytokines can amplify inflammatory response in CSU

How type 2 cytokines can amplify inflammatory response in CSU

expert video
Bullous Pemphigoid Mechanism of Disease Video

Bullous Pemphigoid Mechanism of Disease Video

videoanimation
Diagnosis of Bullous Pemphigoid Interactive Patient Case

Diagnosis of Bullous Pemphigoid Interactive Patient Case

interactivity
Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

expert video
Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

expert video
Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

expert video
Is Pediatric AD Linked to Other Allergic Diseases?

Is Pediatric AD Linked to Other Allergic Diseases?

expert video
Long-term Impacts of AD and the Potential Benefit of Early Intervention

Long-term Impacts of AD and the Potential Benefit of Early Intervention

expert video
New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

expert video
Practical Considerations in Older Patients with AD

Practical Considerations in Older Patients with AD

expert video
The Benefits of Early Intervention in AD: More Than Skin Deep

The Benefits of Early Intervention in AD: More Than Skin Deep

expert video
The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

expert video
The Cumulative Disease Burden of AD in Adult Patients

The Cumulative Disease Burden of AD in Adult Patients

expert video
What do we mean by disease control in AD?

What do we mean by disease control in AD?

expert video
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

Podcast
ADVENT On Air | Exploring PN as a Distinct and Unique Disease

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Podcast
The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Infographic
Stepping Into Hand and Foot Dermatitis

Stepping Into Hand and Foot Dermatitis

expert video
Understanding Disease Mechanisms

Understanding Disease Mechanisms

expert video
Guideline-Based Diagnosis of Atopic Dermatitis

Guideline-Based Diagnosis of Atopic Dermatitis

interactivity
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

expert video
Pathophysiology of Blister Formation in Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

expert video
Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

expert video
What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregiver

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

expert video
Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in BP

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

expert video
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Podcast
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

expert video
Scratching the Surface: Understanding Itch in Prurigo Nodularis

Scratching the Surface: Understanding Itch in Prurigo Nodularis

expert video
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Skin Dyspigmentation In Prurigo Nodularis (PN)

Skin Dyspigmentation In Prurigo Nodularis (PN)

interactivity
Unveiling Atopic Dermatitis

Unveiling Atopic Dermatitis

expert video
Identification and Management of AD Uncontrolled With Topical Therapies in Children

Identification and Management of AD Uncontrolled With Topical Therapies in Children

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
Key Treatment Considerations for Management of Atopic Dermatitis in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

expert video
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

expert video
The Pathophysiology of Prurigo Nodularis

The Pathophysiology of Prurigo Nodularis

videoanimation
Skin Dyspigmentation In Prurigo Nodularis (PN)

Skin Dyspigmentation In Prurigo Nodularis (PN)

interactivity
Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice

Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice

expert video
Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis

Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis

expert video
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

expert video
Itch and Inflammation in Two Distinct Diseases: PN and CSU

Itch and Inflammation in Two Distinct Diseases: PN and CSU

expert video
Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU

Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU

expert video
The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis

The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis

expert video

Learning objectives

  • Highlight the long-term persistence and chronic nature of CSU
Tags
chronic inflammationchronic pruritus
MAT-US-2513535 v2.0 - P Exp Date: 10/27/2027

About this expert

Dermatology

Elena Netchiporouk

MD, MSc, FRCPC

Assistant Professor, Division of Dermatology, McGill University

See author’s profile
Elena Netchiporouk

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region